Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

Heritage Bio Labs

Research Library

Explore 411 articles about peptides, research compounds and related topics, with links to the original studies.

Browse by productGeneral topics

Find articles

Matching articles

Showing 85–96 of 124 articles · Check methods and identity

Clear search and filters

  • Check methods and identity

    What the Current US Bremelanotide Label Covers

    PT-141 is a name used for bremelanotide, a cyclic peptide that activates melanocortin receptors. A defined prescription product, Vyleesi, is FDA approved for a specific condition. The October 2026 US prescribing information explains which people and circumstances were included in that indication.

    PT-1411 source (2026)

  • Check methods and identity

    How Two Phase 3 Trials Measured Desire and Distress Separately

    Bremelanotide, also called PT-141, is a melanocortin receptor agonist. Two older phase 3 studies directly tested the prescription candidate in premenopausal women with hypoactive sexual desire disorder. The 2026 label still summarizes these pivotal comparisons.

    PT-1412 sources (2019, 2026)

  • Check methods and identity

    What the 2026 Bremelanotide Label Reports About Safety

    PT-141 is also known as bremelanotide. The October 2026 US label for the approved product, Vyleesi, records safety findings from its clinical evaluation. Those findings apply to that specific drug product and the settings in which it was studied.

    PT-1411 source (2026)

  • Check methods and identity

    What a three-sample retatrutide analysis showed about labeling

    Retatrutide is an investigational peptide that activates the GIP, GLP-1 and glucagon receptors. The “GLP-3” wording is a catalog label. A 2026 Australian paper examined a different question from the clinical trials.

    RETA GLP-32 sources (2026)

  • Check methods and identity

    What the first TRANSCEND diabetes trial measured

    Retatrutide is an investigational peptide that acts at GIP, GLP-1 and glucagon receptors. The catalog’s “GLP-3” wording describes this entry rather than a receptor.

    RETA GLP-32 sources (2026)

  • Check methods and identity

    What the lab would have to verify about a preparation with both molecules

    Retatrutide is an investigational peptide with activity at GIP, GLP-1 and glucagon receptors. IGF-1 LR3 is an engineered insulin-like growth factor protein. Research about making each material provides background for asking how scientists would verify a preparation containing both.

    RETA / IGF-1 LR33 sources (2023, 2026)

  • Check methods and identity

    What the Early Selank Comparisons Measured About Anxiety

    Selank is a synthetic seven-amino-acid peptide modeled on a peptide called tuftsin. It has been investigated in anxiety research. The direct clinical comparisons described here are older: a search of recent indexed articles did not identify a newer original trial that answered the same question.

    Selank2 sources (2008, 2014)

  • Check methods and identity

    What Brain Connectivity Imaging Can Tell Us About Selank

    Selank is a synthetic peptide modeled on tuftsin. An older study investigated whether Selank or a different peptide, Semax, changed patterns on brain scans in healthy volunteers. Its measurements were about brain activity at rest.

    Selank1 source (2020)

  • Check methods and identity

    Why a kidney trial measured body water as well as lean mass

    Semaglutide acts at the GLP-1 receptor. IGF-1 LR3 is an altered, extended version of the growth-factor protein IGF-1. The 2026 SMART analysis studied semaglutide alone versus placebo and asked whether changes in body composition were related to kidney measurements.

    SEMA / IGF-1 LR32 sources (2023, 2026)

  • Check methods and identity

    What separate Alzheimer’s studies measured for these two molecules

    Semaglutide is a modified GLP-1 receptor agonist peptide. IGF-1 LR3 is an engineered growth-factor protein. Researchers have studied each in connection with Alzheimer’s disease in very different settings.

    SEMA / IGF-1 LR33 sources (2024, 2026)

  • Check methods and identity

    What binding-protein measurements tell us about semaglutide

    Semaglutide activates the GLP-1 receptor. IGF-1 LR3 is a modified insulin-like growth factor protein with altered binding properties. An older human study measured IGF-binding proteins during semaglutide treatment.

    SEMA / IGF-1 LR32 sources (1992, 2025)

  • Check methods and identity

    What Semax Changed in Gene Measurements After Experimental Ischemia

    Semax is a synthetic peptide based in part on a region of adrenocorticotropic hormone. Researchers have used it in animal studies to ask whether parts of the brain respond differently after temporary loss and restoration of blood flow.

    Semax1 source (2024)

Browse by product

General topics

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Library index (JSON)